Epigenic Therapeutics to Present Preclinical Data of EPI-003, a Novel Epigenetic Therapy for Chronic Hepatitis B, at AASLD 2024

Shanghai, China, October 26, 2024 — Epigenic Therapeutics, Inc., a cutting-edge biotechnology company dedicated to treating various diseases through epigenetic regulation and developing next-generation epigenetic therapies, announced today thatNovember 15-19, 2024InSan Diego, California, USAHeldOral Presentation at the 2024 American Association for the Study of Liver Diseases (AASLD), The title of the report is"Epigenetic Regulation Technology Effectively and Durably Eliminates HBsAg and Achieves Serological Conversion in HBV Mouse Models"。

This report will focus on introducingLatest Advances in Preclinical Studies of EPI-003, a Drug Developed Based on Epigenetic Regulation TechnologyAs a novel mechanism-based HBV antiviral drug, EPI-003 has demonstrated significant advantages over other hepatitis B treatment drugs in research, effectively clearing HBV surface antigens, reducing HBV DNA levels, and showing no rebound in preclinical studies. Moreover, by directly blocking the transcription of HBV cccDNA, EPI-003 can continuously eliminate HBsAg, restore the host's immune response to HBV, and exhibit the therapeutic potential for functional or complete cure in patients with chronic HBV infection.